Autoreactive CD4+ T cell (CD4+ T cell) (CD4+ T cell)

Autoreactive CD4+ T cells are a subset of helper T lymphocytes that recognize self-peptides presented by Major Histocompatibility Complex (MHC) class II molecules, leading to an inappropriate immune response against the body's own tissues (National Institute of Allergy and Infectious Diseases [NIAID], 2023). In a healthy immune system, these cells are typically eliminated in the thymus or suppressed in the periphery by regulatory T cells; however, their persistence and activation are hallmarks of autoimmune diseases such as multiple sclerosis, type 1 diabetes, and rheumatoid arthritis (Nature Reviews Immunology, 2020). Once activated, these cells secrete pro-inflammatory cytokines like IFN-gamma and IL-17, which orchestrate a broader immune attack involving B cells and macrophages (PubMed, 2021). Therapeutic targeting of these cells involves various strategies, including the use of monoclonal antibodies like Teplizumab to modulate CD3 signaling or Abatacept to block costimulatory pathways necessary for T-cell activation (FDA, 2022; Bristol Myers Squibb, 2023). Additionally, drugs like Natalizumab prevent these cells from crossing the blood-brain barrier, thereby limiting damage in the central nervous system (Biogen, 2021). Current research is heavily focused on developing antigen-specific therapies that can selectively silence or delete these autoreactive clones without compromising the overall integrity of the immune system (Journal of Clinical Investigation, 2022).

Other names

Self-reactive CD4+ T cellsPathogenic CD4+ T cellsAutoreactive helper T cellsMHC class II-restricted autoreactive T cells

Modulation of T-cell receptor signaling, blockade of costimulatory signals, inhibition of lymphocyte trafficking to inflamed tissues, and induction of peripheral immune tolerance.